Literature DB >> 10198801

Group A streptococcal vaccines.

J B Dale1.   

Abstract

The pathogenesis of group A streptococcal infections, and antigens that contribute to protective immune responses are reviewed. Several approaches to vaccine development are discussed. Data are provided from preclinical studies of multivalent M protein-based vaccines that evoke protective antibodies in laboratory animals. Also discussed are future strategies for the development of broadly protective vaccines, and their potential impact on the incidence of streptococcal infections, and acute rheumatic fever.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10198801     DOI： 10.1016/s0891-5520(05)70052-0

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN： 0891-5520            Impact factor:   5.982


  9 in total

Review 1.  Worldwide perspective of valve disease.

Authors:  J Soler-Soler; E Galve
Journal:  Heart       Date:  2000-06       Impact factor: 5.994

2.  Current and Future Use of Vaccines for Viral and Bacterial Respiratory Tract Infections.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-04       Impact factor: 3.725

3.  Multilocus analysis of extracellular putative virulence proteins made by group A Streptococcus: population genetics, human serologic response, and gene transcription.

Authors:  S D Reid; N M Green; J K Buss; B Lei; J M Musser
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-19       Impact factor: 11.205

4.  The NH(2)-terminal region of Streptococcus pyogenes M5 protein confers protection against degradation by proteases and enhances mucosal colonization of mice.

Authors:  Thomas A Penfound; Itzhak Ofek; Harry S Courtney; David L Hasty; James B Dale
Journal:  J Infect Dis       Date:  2010-05-15       Impact factor: 5.226

5.  Streptococcus pyogenes genes that promote pharyngitis in primates.

Authors:  Luchang Zhu; Randall J Olsen; Stephen B Beres; Matthew Ojeda Saavedra; Samantha L Kubiak; Concepcion C Cantu; Leslie Jenkins; Andrew S Waller; Zhizeng Sun; Timothy Palzkill; Adeline R Porter; Frank R DeLeo; James M Musser
Journal:  JCI Insight       Date:  2020-06-04

6.  New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci.

Authors:  James B Dale; Thomas A Penfound; Edna Y Chiang; William J Walton
Journal:  Vaccine       Date:  2011-09-13       Impact factor: 3.641

7.  Antibodies against a synthetic peptide of SagA neutralize the cytolytic activity of streptolysin S from group A streptococci.

Authors:  James B Dale; Edna Y Chiang; David L Hasty; Harry S Courtney
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

8.  Postgenomic analysis of four novel antigens of group a streptococcus: growth phase-dependent gene transcription and human serologic response.

Authors:  Sean D Reid; Nicole M Green; Gail L Sylva; Jovanka M Voyich; Elisha T Stenseth; Frank R DeLeo; Timothy Palzkill; Donald E Low; Harry R Hill; James M Musser
Journal:  J Bacteriol       Date:  2002-11       Impact factor: 3.490

9.  Group A Streptococcus gene expression in humans and cynomolgus macaques with acute pharyngitis.

Authors:  Kimmo Virtaneva; Morag R Graham; Stephen F Porcella; Nancy P Hoe; Hua Su; Edward A Graviss; Tracie J Gardner; James E Allison; William J Lemon; John R Bailey; Michael J Parnell; James M Musser
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.